

You could take part
in a research study
for hereditary
angioedema (HAE).




We thank you for your
interest in the [redacted]
[redacted] Study!

FOR ADOLESCENTS (12-17)

What if you could break
free from HAE attacks?



A research study for
prevention of hereditary
angioedema (HAE) attacks.





About the [REDACTED] Study

The [REDACTED] Study is a clinical research study for people living with HAE type 1 or 2. The study is testing the safety and efficacy of an investigational drug, called [REDACTED] for preventing HAE attacks when it's taken as a daily tablet for a long period of time.

This is a phase 3 open-label study, which means that the study drug has already been tested in other studies before and has shown good safety and efficacy results.

Participation in the [REDACTED] Study will last about two and a half years, and there will be dedicated on-site visits as well as visits that will be completed virtually via a phone or smart device.

The study will include three defined periods:



Screening

Time commitment: 1 day

To confirm eligibility for the study, potential participants will undergo a screening visit at the study site. If a potential participant is currently in another HAE study using [REDACTED], this visit might happen on the last day of that study.



Treatment

Time commitment: 2.5 years

Participants will take the study drug tablet once every day and will have three on-site study visits in the first month, followed by six monthly on-site visits and phone calls in between.

- During this period, participants will be asked to complete an electronic diary (eDiary). The eDiary will be used to record:
 - Intake of the study drug
 - HAE attack symptoms and how they are feeling
 - Details about any HAE attacks
 - If other medicines were taken for an HAE attack



Follow-up

Time commitment: 2 weeks

After participants have stopped taking the study drug, they will go back to the study site so that the study doctor can check on their health.

Who can join the study

Diversity in clinical research is important. This study is looking to include people from all different backgrounds to represent people of every gender, race, ethnicity, and age.

To be considered for enrollment in the [REDACTED] Study, interested individuals must:

- Be 12 years of age or older
 - Have a confirmed diagnosis of HAE type 1 or 2
 - Have either:
 - Participated in the [REDACTED] Study, [REDACTED] Study, or any [REDACTED] study
- OR
- Experienced at least one HAE attack within the past three months (no previous study participation required)
 - If taking a long-term preventative treatment before screening: must experience at least one attack within the three months before starting that treatment

There are other requirements, which the study doctor will discuss with you and your parent/guardian.

For more information, you and your parent/guardian may talk to your doctor, visit [TBDURL.com](https://www.tbdu.com), or contact the participating research site

